Quince Therapeutics, Inc. Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>Quince Therapeutics, Inc. filed its Definitive Proxy Statement (DEF 14A) detailing executive compensation and corporate governance for the period ending June 5, 2024.</b>

AI Summary

Quince Therapeutics, Inc. (QNCX) filed a Proxy Statement (DEF 14A) with the SEC on April 24, 2024. Quince Therapeutics, Inc. (formerly Cortexyme, Inc.) filed a Definitive Proxy Statement (DEF 14A). The filing covers the period ending June 5, 2024, and was filed on April 24, 2024. The company's principal executive offices are located at 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080. The company's IRS number is 901024039 and it is incorporated in California. The filing includes detailed information regarding executive compensation and equity awards for fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking Quince Therapeutics, Inc., this filing contains several important signals. This filing provides shareholders with crucial information regarding the company's leadership, compensation structures, and upcoming voting matters, enabling informed participation in corporate decisions. As a DEF 14A filing, it is a standard disclosure for companies holding shareholder meetings, outlining proposals and the board's recommendations, which can influence investor sentiment and proxy advisor recommendations.

Risk Assessment

Risk Level: low — Quince Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial performance data or significant operational updates, indicating a low level of immediate risk.

Analyst Insight

Review the executive compensation details and any proposed shareholder resolutions to understand potential impacts on corporate governance and shareholder value.

Key Numbers

• 2021-01-01 — Fiscal Year Start (Data for fiscal year 2021)
• 2021-12-31 — Fiscal Year End (Data for fiscal year 2021)
• 2022-01-01 — Fiscal Year Start (Data for fiscal year 2022)
• 2022-12-31 — Fiscal Year End (Data for fiscal year 2022)
• 2023-01-01 — Fiscal Year Start (Data for fiscal year 2023)
• 2023-12-31 — Fiscal Year End (Data for fiscal year 2023)

Key Players & Entities

• Quince Therapeutics, Inc. (company) — Filer name
• Cortexyme, Inc. (company) — Former company name
• DEF 14A (document) — Filing type
• 2024-04-24 (date) — Filing date
• 2024-06-05 (date) — Period of report
• 611 Gateway Blvd., Suite 273, South San Francisco, CA 94080 (address) — Business address
• 901024039 (identifier) — IRS number
• CA (location) — State of incorporation

FAQ

Key Dates

• 2024-04-24: Filing Date — Definitive Proxy Statement (DEF 14A) filed.
• 2024-06-05: Reporting Period End — The period covered by the proxy statement.
• 2016-01-04: Name Change Date — Date Quince Therapeutics, Inc. changed its name from Cortexyme, Inc.

Filing Documents

• d75541ddef14a.htm (DEF 14A) — 684KB
• g75541g02s02.jpg (GRAPHIC) — 33KB
• g75541g35g35.jpg (GRAPHIC) — 107KB
• g75541g36g36.jpg (GRAPHIC) — 115KB
• g75541page026.jpg (GRAPHIC) — 209KB
• g75541page027.jpg (GRAPHIC) — 260KB
• g75541page028.jpg (GRAPHIC) — 225KB
• 0001193125-24-110034.txt (&nbsp;) — 3964KB
• qncx-20231231.xsd (EX-101.SCH) — 6KB
• qncx-20231231_def.xml (EX-101.DEF) — 7KB
• qncx-20231231_lab.xml (EX-101.LAB) — 9KB
• qncx-20231231_pre.xml (EX-101.PRE) — 6KB
• d75541ddef14a_htm.xml (XML) — 235KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 32 EXECUTIVE OFFICERS 34

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 35 DIRECTOR COMPENSATION 45 EQUITY COMPENSATION PLAN INFORMATION 47 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 48 HOUSEHOLDING OF PROXY MATERIALS 50 ADDITIONAL INFORMATION 51 OTHER MATTERS 51 i Table of Contents QUINCE THERAPEUTICS, INC. PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON WEDNESDAY, JUNE 5, 2024 APRIL 24, 2024 INFORMATION ABOUT SOLICITATION AND VOTING The accompanying proxy is solicited on behalf of our board of directors of Quince Therapeutics, Inc. (the "Company" or "Quince"), for use at Quince's 2024 Annual Meeting of Stockholders (the "Annual Meeting" or the "meeting"), to be held on Wednesday, June 5, 2024 at 10:00 a.m. Pacific Time via live webcast on the internet at https://web.lumiconnect.com/294872708. References in the Proxy Statement to "we," "us," "our," "the Company" or "Quince" refer to Quince Therapeutics, Inc. INTERNET AVAILABILITY OF PROXY MATERIALS We will mail, on or about Wednesday, April 24, 2024, the Notice of Internet Availability of Proxy Materials (the "Notice"), to our stockholders of record and beneficial owners at the close of business on Thursday, April 18, 2024 (the "Record Date"). On the date of mailing of the Notice, all stockholders and beneficial owners will have the ability to access all of the proxy materials on a website referred to in the Notice. These proxy materials will be available free of charge. The Notice will identify the website where the proxy materials will be made available; the date, the time and location of the Annual Meeting; the matters to be acted upon at the meeting and our board of directors' recommendations with regard to each matter; a toll-free telephone number, an e-mail address, and a website where stockholders can request a paper or e-mail copy of the Proxy Statement; our Annual Report on Form 10-K for the year ended December 31, 2023 (our "Annual Report"), and a form of proxy relating

View Full Filing

View this DEF 14A filing on SEC EDGAR